Some patients and doctors say it is hard to find Pfizer's COVID-19 pill Paxlovid

Some patients and doctors say it is hard to find Pfizer’s COVID-19 pill Paxlovid

COVID-19 cases and hospitalizations are increasing as part of what some refer to as an “invisible wave,” meaning more attention is being paid to Paxlovid, Pfizer Inc’s PFE.
Antiviral treatment that can prevent some people from developing serious illnesses.

The pill has become an increasingly important tool in the nation’s defense against COVID-19 as mandates for mask have been lifted and people have returned to their not-too-distant lives.

With this elevated situation, challenges of supply and access have arisen.

“In the past week, I’ve had several state public health departments come to us saying access to a prescribing event is the problem,” Carolyn Savillo, chief commercial officer at Color, who supports a program in Massachusetts that uses telehealth to determine the eligibility of a person What to get for Paxlovid, he told Stat this week.

According to Kaiser Health News, it’s unclear how often Paxlovid is used or how much of a supply is available within certain communities. And it is not always easy to find a prescription; One individual told NPR that it took “an extraordinary amount of knowledge, connections, and assurance” to get the drug.

Healthcare providers are also wrestling with what to do if a patient taking baxlovid reports a relapse of symptoms, a new concern that has emerged in recent weeks.

“This is something that public health agencies have to get their hands on and think about what they should be doing,” Michael Charnes, chief of staff for the VA Boston Healthcare System, told the Wall Street Journal.

Pfizer said patients who experience a relapse should take another course of treatment, although US regulators disagree with that assessment.

And as more people use the tests at home, they may not realize they need to start baxlovid within five days of developing symptoms if they test positive, said Dr. Michael Mina, a former Harvard epidemiologist who is now chief science officer at eMed. , which connects at-home testing with telehealth services, according to MarketWatch this week.

“People don’t just act on their self-examination, and they also don’t report, so it’s kind of a double whammy,” he said.

Other COVID-19 news you should know:

  • The Biden administration said Thursday that it plans to share patents for a so-called stabilized spike protein — a component of many COVID-19 vaccines — with other countries as part of an effort to vaccinate more of the world. It is unclear how this will affect companies such as BioNTech SE BNTX,
    + 0.53%And
    Pfizer, Johnson & Johnson JNJ,
    and Moderna Inc. mRNA,
    + 5.95%And
    that developed the vaccines that are currently available in the United States, according to the journal. Patent news came from Thursday’s COVID-19 Summit.

  • The White House also continues to make arguments for more COVID-19 funding in the United States as it prepares for a possible increase in the number of cases in the fall and winter. A portion of this funding will be used to pay for the next generation of COVID-19 that may better protect against current (and future) strains of the virus. “If we’re willing to stay in the back row and get our vaccines in the spring, we have plenty of time,” Dr. Ashish Jha, the White House COVID-19 coordinator, told The Associated Press this week. “But then we missed the fall and winter entirely. That is not an acceptable outcome, I think, for the American people.”

Here’s what the numbers say:

The daily average of new COVID-19 cases rose to its highest level in three months; The average of new cases in seven days was 87,522 on Thursday, the highest number seen since February 21, according to the New York Times Tracker. Mississippi was the state with the largest increase in new cases in two weeks, followed by Missouri.

The daily rate of hospitalizations was 20,070, up 20% from the past two weeks and the highest daily average since March 23. Meanwhile, the daily death rate was 321, down 4% from the previous two weeks. – Tommy Kilgore

2022-05-13 14:34:00

Leave a Comment

Your email address will not be published. Required fields are marked *